Malcolm S Mitchell

Summary

Publications

  1. ncbi request reprint Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma
    Malcolm S Mitchell
    University of California, San Diego, School of Medicine and Cancer Center, San Diego, CA, USA
    J Clin Oncol 25:2078-85. 2007
  2. ncbi request reprint Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma
    Malcolm S Mitchell
    Center for Biological Therapy and Melanoma Research, University of California, San Diego, La Jolla, California, USA
    Clin Cancer Res 10:76-83. 2004
  3. ncbi request reprint Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope
    Malcolm S Mitchell
    Center for Biological Therapy and Melanoma Research, University of California San Diego School of Medicine, San Diego, CA, USA
    J Clin Oncol 20:1075-86. 2002
  4. ncbi request reprint Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa
    Malcolm S Mitchell
    Hudson Webber Cancer Research Center, Karmanos Cancer Institute, 110 East Warren Avenue, Suite 740, Detroit, MI 48201, USA
    Cancer Invest 20:759-68. 2002
  5. ncbi request reprint Combinations of anticancer drugs and immunotherapy
    Malcolm S Mitchell
    Biological Therapy Program, Karmanos Cancer Institute, 110 East Warren Avenue, Detroit, MI 48201 1379, USA
    Cancer Immunol Immunother 52:686-92. 2003
  6. ncbi request reprint Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha
    Ulka Vaishampayan
    Karmanos Cancer Institute, Department of Medicine, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 8:3696-701. 2002
  7. ncbi request reprint Cancer vaccines, a critical review--Part II
    Malcolm S Mitchell
    Karmanos Cancer Institute, Detroit, MI 48201, USA
    Curr Opin Investig Drugs 3:150-8. 2002
  8. ncbi request reprint Immunotherapy as part of combinations for the treatment of cancer
    Malcolm S Mitchell
    Biological Therapy, Karmanos Cancer Institute, Detroit, MI 48201, USA
    Int Immunopharmacol 3:1051-9. 2003
  9. ncbi request reprint Synopsis of the 4th Walker's Cay Meeting on Cancer Vaccines, 7-10 March 2002
    Malcolm S Mitchell
    Wayne State University, Karmanos Cancer Institute, Room 740, 110 E Warren Avenue, Detroit, MI 48201, USA
    Cancer Immunol Immunother 51:674-6. 2002
  10. ncbi request reprint Synopsis of the 5th annual Cancer Vaccines and Immunotherapy Colloquium at Walker's Cay
    Malcolm S Mitchell
    Van Elslander Cancer Center, 19229 Mack Avenue, Grosse Pointe Woods, MI 48236, USA
    Cancer Immunol Immunother 52:655-60. 2003

Detail Information

Publications13

  1. ncbi request reprint Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma
    Malcolm S Mitchell
    University of California, San Diego, School of Medicine and Cancer Center, San Diego, CA, USA
    J Clin Oncol 25:2078-85. 2007
    ..To compare the overall survival (OS) of patients with resected stage III melanoma administered active specific immunotherapy and low-dose interferon alfa-2b (IFN-alpha-2b) with the OS achieved using high-dose IFN-alpha-2b...
  2. ncbi request reprint Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma
    Malcolm S Mitchell
    Center for Biological Therapy and Melanoma Research, University of California, San Diego, La Jolla, California, USA
    Clin Cancer Res 10:76-83. 2004
    ..Computed tomography scans were performed pretreatment and at week 12 to measure possible beneficial effects on known lesions...
  3. ncbi request reprint Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope
    Malcolm S Mitchell
    Center for Biological Therapy and Melanoma Research, University of California San Diego School of Medicine, San Diego, CA, USA
    J Clin Oncol 20:1075-86. 2002
    ..To study distribution and toxicity of cytolytic T lymphocytes (CTLs) against a single melanoma epitope...
  4. ncbi request reprint Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa
    Malcolm S Mitchell
    Hudson Webber Cancer Research Center, Karmanos Cancer Institute, 110 East Warren Avenue, Suite 740, Detroit, MI 48201, USA
    Cancer Invest 20:759-68. 2002
  5. ncbi request reprint Combinations of anticancer drugs and immunotherapy
    Malcolm S Mitchell
    Biological Therapy Program, Karmanos Cancer Institute, 110 East Warren Avenue, Detroit, MI 48201 1379, USA
    Cancer Immunol Immunother 52:686-92. 2003
    ....
  6. ncbi request reprint Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha
    Ulka Vaishampayan
    Karmanos Cancer Institute, Department of Medicine, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 8:3696-701. 2002
    ..In this Phase II trial, the combination of cyclophosphamide, Melacine, and IFNalpha was tested in metastatic malignant melanoma...
  7. ncbi request reprint Cancer vaccines, a critical review--Part II
    Malcolm S Mitchell
    Karmanos Cancer Institute, Detroit, MI 48201, USA
    Curr Opin Investig Drugs 3:150-8. 2002
    ..Finally, a greater understanding of ways in which tumors escape immunological detection or thwart immunological responses should lead to improved strategies against the tumor to augment the effect of vaccination...
  8. ncbi request reprint Immunotherapy as part of combinations for the treatment of cancer
    Malcolm S Mitchell
    Biological Therapy, Karmanos Cancer Institute, Detroit, MI 48201, USA
    Int Immunopharmacol 3:1051-9. 2003
    ..Trials of antibodies and chemotherapy have been limited. It appears that trastuzumab (Herceptin) potentiates antitumor therapy in breast cancer and also increases the cardiotoxicity of those regimens...
  9. ncbi request reprint Synopsis of the 4th Walker's Cay Meeting on Cancer Vaccines, 7-10 March 2002
    Malcolm S Mitchell
    Wayne State University, Karmanos Cancer Institute, Room 740, 110 E Warren Avenue, Detroit, MI 48201, USA
    Cancer Immunol Immunother 51:674-6. 2002
  10. ncbi request reprint Synopsis of the 5th annual Cancer Vaccines and Immunotherapy Colloquium at Walker's Cay
    Malcolm S Mitchell
    Van Elslander Cancer Center, 19229 Mack Avenue, Grosse Pointe Woods, MI 48236, USA
    Cancer Immunol Immunother 52:655-60. 2003
  11. ncbi request reprint Cancer vaccines, a critical review--Part I
    Malcolm S Mitchell
    Karmanos Cancer Institute, Detroit, MI 48201, USA
    Curr Opin Investig Drugs 3:140-9. 2002
    ....
  12. ncbi request reprint Chemotherapy for melanoma: the resultant of conflicting vectors
    Malcolm S Mitchell
    J Clin Oncol 22:2043-5. 2004
  13. ncbi request reprint Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma
    Gilda G Hillman
    Department of Radiation Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine and Harper Hospital, Detroit, MI 48201, USA
    Hum Gene Ther 14:763-75. 2003
    ..Administering radiation before this novel gene therapy approach, that creates an in situ tumor vaccine, holds promise for the treatment of human prostate carcinoma...